Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization

Diabetic retinopathy is an ischemic retinal neovascular disease causing vision loss among adults. The studies presented involve the design and testing of a gene therapy vector to inhibit retinal revascularization, similar to that found in diabetic retinopathy. Gene therapy has proven to be an effect...

Full description

Bibliographic Details
Other Authors: Biswal, Manas Ranjan.
Format: Others
Language:English
Published: Florida Atlantic University
Subjects:
Online Access:http://purl.flvc.org/FAU/3359290
id ndltd-fau.edu-oai-fau.digital.flvc.org-fau_4070
record_format oai_dc
spelling ndltd-fau.edu-oai-fau.digital.flvc.org-fau_40702019-07-04T03:54:09Z Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization Biswal, Manas Ranjan. Text Electronic Thesis or Dissertation Florida Atlantic University English xiv, 92 p. : ill. (some col.) electronic Diabetic retinopathy is an ischemic retinal neovascular disease causing vision loss among adults. The studies presented involve the design and testing of a gene therapy vector to inhibit retinal revascularization, similar to that found in diabetic retinopathy. Gene therapy has proven to be an effective method to introduce therapeutic proteins to treat retinal diseases. Targeting a specific cell type and expression of therapeutic proteins according to the tissue microenvironment should have an advantage over traditional gene therapy by avoiding unwanted transgene expression. Hypoxia plays a significant role in the pathophysiology of many retinal ischemic diseases. Retinal Mèuller cells provide structural and functional support to retinal neurons, as well as playing a significant role in retinal neovascularization. Targeting Mèuller cells may be an effective strategy to prevent retinal neovascularization under pathological conditions. ... The hypoxia regulated, glial specific vector successfully reduced the abnormal neovascularization in the periphery by 93% and reduced the central vasobliterated area by 90%. A substantial amount of exogenous endostatin was produced in the retinas of P17 OIR mice. A significant increase in human endostatin protein and reduced vascular endothelial growth factor (VEGF) were identified by Western blot and ELISA, respectively. These findings suggest hypoxia-regulated, glial cell-specific scAAV mediated gene expression may be useful to prevent blindness found in devastating retinal diseases involving neovascularization. by Manas Ranjan Biswal. Thesis (Ph.D.)--Florida Atlantic University, 2012. Includes bibliography. Mode of access: World Wide Web. System requirements: Adobe Reader. Diabetic retinopathy--Research--Methodology Gene therapy Retinal degeneration--Treatment Neovascularization inhibitors Mitochondrial pathology Retina--Cytology Gene mapping http://purl.flvc.org/FAU/3359290 837279370 3359290 FADT3359290 fau:4070 Charles E. Schmidt College of Science Center for Complex Systems and Brain Sciences http://rightsstatements.org/vocab/InC/1.0/ https://fau.digital.flvc.org/islandora/object/fau%3A4070/datastream/TN/view/Hypoxia-regulated%20glial%20cell-specific%20gene%20therapy%20to%20treat%20retinal%20neovascularization.jpg
collection NDLTD
language English
format Others
sources NDLTD
topic Diabetic retinopathy--Research--Methodology
Gene therapy
Retinal degeneration--Treatment
Neovascularization inhibitors
Mitochondrial pathology
Retina--Cytology
Gene mapping
spellingShingle Diabetic retinopathy--Research--Methodology
Gene therapy
Retinal degeneration--Treatment
Neovascularization inhibitors
Mitochondrial pathology
Retina--Cytology
Gene mapping
Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization
description Diabetic retinopathy is an ischemic retinal neovascular disease causing vision loss among adults. The studies presented involve the design and testing of a gene therapy vector to inhibit retinal revascularization, similar to that found in diabetic retinopathy. Gene therapy has proven to be an effective method to introduce therapeutic proteins to treat retinal diseases. Targeting a specific cell type and expression of therapeutic proteins according to the tissue microenvironment should have an advantage over traditional gene therapy by avoiding unwanted transgene expression. Hypoxia plays a significant role in the pathophysiology of many retinal ischemic diseases. Retinal Mèuller cells provide structural and functional support to retinal neurons, as well as playing a significant role in retinal neovascularization. Targeting Mèuller cells may be an effective strategy to prevent retinal neovascularization under pathological conditions. ... The hypoxia regulated, glial specific vector successfully reduced the abnormal neovascularization in the periphery by 93% and reduced the central vasobliterated area by 90%. A substantial amount of exogenous endostatin was produced in the retinas of P17 OIR mice. A significant increase in human endostatin protein and reduced vascular endothelial growth factor (VEGF) were identified by Western blot and ELISA, respectively. These findings suggest hypoxia-regulated, glial cell-specific scAAV mediated gene expression may be useful to prevent blindness found in devastating retinal diseases involving neovascularization. === by Manas Ranjan Biswal. === Thesis (Ph.D.)--Florida Atlantic University, 2012. === Includes bibliography. === Mode of access: World Wide Web. === System requirements: Adobe Reader.
author2 Biswal, Manas Ranjan.
author_facet Biswal, Manas Ranjan.
title Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization
title_short Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization
title_full Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization
title_fullStr Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization
title_full_unstemmed Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization
title_sort hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization
publisher Florida Atlantic University
url http://purl.flvc.org/FAU/3359290
_version_ 1719219189988720640